Compare Bristol-Myers Squibb Co (BMY) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BMY | XLY | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $124.52 |
52-Week Low | $42.60 | $105.64 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
XLY trades at $117.89, down 1.49% today, but maintains a bullish technical outlook with strong moving average support. The ETF benefits from positive analyst sentiment with a 100% buy rating and recent coverage highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions with RSI readings above 70, but the overall trend remains positive with key support at $118.
The consumer discretionary sector faces headwinds from inflation pressures, but XLY's diversified exposure positions it for recovery. Near-term risks include consumer spending sensitivity to economic conditions, while the bullish analyst consensus and technical momentum suggest potential upside if market conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
